Episurf Medical AB (STO:EPISB), a provider of minimally invasive and personalised treatment alternatives for people with painful joint injuries, announced on Friday that it has CE-marked a new knee joint visualisation tool, which will be released to the European market following a controlled launch process.
This tool, named Epioscopy, is a web-based application based on artificial intelligence (AI), providing an overview of a knee joint's clinical condition.
According to the company, Epioscopy is intended to assist healthcare professionals in their planning of optimal treatments for patients' knees by interactive 3D visualisation of structures and possible structural deviations.
Episurf Medical offers the Episealer personalised implants and Epiguide surgical drill guides, which are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention.
Karyopharm Therapeutics awards inducement grants to new employees
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition